Novo Nordisk's Diabetes Drug Outshines Ozempic: Buy?
A new diabetes drug from Novo Nordisk could change the GLP-1 landscape. This deep dive breaks down what investors sho...
Which index fund performed best this year? Review top performers, volatility, and potential shifts to inform your next move.
26,831 articlesA new diabetes drug from Novo Nordisk could change the GLP-1 landscape. This deep dive breaks down what investors sho...
In a bid to curb pump prices, the Trump administration announced a temporary waiver of the Jones Act. Early market re...
Tod Boehly argues that admitting uncertainty is a strength in an AI-powered era. This guide explores what that means ...
A real-world hotel-charge fraud case highlights how easy it is for card data to be misused. This practical guide show...
SoFi’s stock faced a sharp pullback in January. This article breaks down the factors behind the move, what it signals...
A growing body of research finds a minority of workers use AI to enhance thinking through metacognition. The rest rel...
Seven AI models tackle the 2026 World Cup, but what does that mean for investors in crypto? This story parses predict...
A wedding venue owner took more than $1 million from unsuspecting couples and investors. This article uncovers how th...
Southwest Airlines is rolling out a new boarding system that is drawing complaints about overhead-bin squeezes and lo...
Riverside County Sheriff Chad Bianco, a Republican candidate for California governor, says he seized ballots tied to ...
Anthropic unveils Claude Mythos in a full cybersecurity-focused release, paired with a safer Fable 5 for general user...
As AI tools ride into homebuilding, a new asset is emerging: institutional knowledge. Builders that centralize data a...